Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
10%(1 trials)
Terminated
1(6%)

Phase Distribution

Ph not_applicable
4
25%
Ph phase_1
2
13%
Ph phase_2
4
25%
Ph phase_4
4
25%
Ph phase_3
2
13%

Phase Distribution

2

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
2(12.5%)
Phase 2Efficacy & side effects
4(25.0%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
4(25.0%)
N/ANon-phased studies
4(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Active(1)
Completed(10)
Terminated(1)
Other(4)

Detailed Status

Completed10
unknown4
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (12.5%)
Phase 24 (25.0%)
Phase 32 (12.5%)
Phase 44 (25.0%)
N/A4 (25.0%)

Trials by Status

completed1063%
unknown425%
not_yet_recruiting16%
terminated16%

Recent Activity

0 active trials
Showing 5 of 16
not_yet_recruitingphase_2

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

NCT05713799
completednot_applicable

Alpha-lipoic Acid in Critically Ill Patients With Sepsis

NCT06661993
completedphase_4

Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases

NCT04475276
unknownphase_2

Alpha-Lipoic Acid in Patients With Sepsis

NCT05808946
unknownnot_applicable

Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency

NCT05571748
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT05713799Phase 2

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Not Yet Recruiting
NCT06661993Not Applicable

Alpha-lipoic Acid in Critically Ill Patients With Sepsis

Completed
NCT04475276Phase 4

Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases

Completed
NCT05808946Phase 2

Alpha-Lipoic Acid in Patients With Sepsis

Unknown
NCT05571748Not Applicable

Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency

Unknown
NCT03788759Phase 2

Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia

Completed
NCT02937363Not Applicable

Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise

Completed
NCT02666170Not Applicable

Effects of Alpha-acid Lipoic in PCOS Women

Unknown
NCT01524861Phase 4

Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy

Completed
NCT01877590Phase 4

Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

Completed
NCT00112996Phase 3

Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

Completed
NCT00477607Phase 2

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

Completed
NCT01888861Phase 3

Effect of Alpha-lipoic Acid on Biochemical Markers and Important Outcomes in Patients Admitted to Intensive Care Units

Unknown
NCT01406704Phase 4

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Terminated
NCT00079807Phase 1

Painful HIV Neuropathy and Alpha-Lipoic Acid

Completed
NCT00010842Phase 1

Natural Antioxidants in the Treatment of Multiple Sclerosis

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16